Insider Selling: Avalo Therapeutics (NASDAQ:AVTX) Insider Sells $26,100.00 in Stock

Avalo Therapeutics, Inc. (NASDAQ:AVTX) insider Mittie Doyle sold 1,450 shares of the stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $18.00, for a total transaction of $26,100.00. Following the transaction, the insider owned 51,776 shares of the company’s stock, valued at $931,968. This trade represents a 2.72% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Mittie Doyle also recently made the following trade(s):

• On Monday, April 6th, Mittie Doyle sold 3,970 shares of Avalo Therapeutics stock. The shares were sold at an average price of $18.01, for a total transaction of $71,499.70.
• On Wednesday, April 1st, Mittie Doyle sold 679 shares of Avalo Therapeutics stock. The shares were sold at an average price of $16.00, for a total transaction of $10,864.00.

Avalo Therapeutics Trading Up 0.9%

Shares of NASDAQ:AVTX opened at $18.16 on Friday. The company has a market cap of $954.78 million, a price-to-earnings ratio of -3.33 and a beta of 0.83. Avalo Therapeutics, Inc. has a 12 month low of $4.55 and a 12 month high of $24.27. The company has a 50-day moving average price of $15.93 and a 200 day moving average price of $16.11.

Avalo Therapeutics (NASDAQ:AVTX) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.98) earnings per share for the quarter, topping the consensus estimate of ($1.00) by $0.02. As a group, equities analysts forecast that Avalo Therapeutics, Inc. will post -2.58 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on AVTX. BTIG Research restated a “buy” rating and issued a $58.00 price target on shares of Avalo Therapeutics in a research report on Tuesday, June 16th. Piper Sandler reissued an “overweight” rating and issued a $60.00 target price (up from $48.00) on shares of Avalo Therapeutics in a research note on Monday, May 11th. Mizuho raised their target price on shares of Avalo Therapeutics from $39.00 to $45.00 and gave the stock an “outperform” rating in a report on Thursday, May 14th. Citizens Jmp cut their price target on shares of Avalo Therapeutics from $62.00 to $55.00 and set a “market outperform” rating on the stock in a report on Thursday, May 14th. Finally, Wolfe Research started coverage on shares of Avalo Therapeutics in a research report on Thursday, April 9th. They issued an “outperform” rating and a $48.00 price objective on the stock. Twelve investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Avalo Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $46.67.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Caligan Partners LP purchased a new stake in Avalo Therapeutics in the 3rd quarter valued at about $10,592,000. Balyasny Asset Management L.P. purchased a new position in shares of Avalo Therapeutics during the third quarter worth approximately $10,390,000. Vanguard Group Inc. raised its stake in shares of Avalo Therapeutics by 314.9% during the third quarter. Vanguard Group Inc. now owns 692,637 shares of the company’s stock valued at $8,803,000 after acquiring an additional 525,696 shares in the last quarter. Millennium Management LLC raised its stake in shares of Avalo Therapeutics by 380.2% during the fourth quarter. Millennium Management LLC now owns 659,979 shares of the company’s stock valued at $11,985,000 after acquiring an additional 522,548 shares in the last quarter. Finally, Seven Fleet Capital Management LP boosted its holdings in shares of Avalo Therapeutics by 806.0% in the first quarter. Seven Fleet Capital Management LP now owns 573,883 shares of the company’s stock valued at $8,568,000 after purchasing an additional 510,540 shares during the period. Hedge funds and other institutional investors own 87.06% of the company’s stock.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.